Key Highlights

  • Entropy has signed a pre-Clinical Trial Agreement with the University of California, San Francisco, to develop a Phase 2 trial comparing TRP-8803 with escitalopram in up to 80 young adults with Major Depressive Disorder.
  • The trial will be led by Professor Robin Carhart-Harris, described by the company as the world's most cited psychedelic neuroscientist, and is expected to commence in H1 CY27.
  • Entropy will act as FDA Investigational New Drug sponsor, with the trial intended to establish a broader US regulatory pathway for TRP-8803.
  • The trial will be funded from existing cash reserves, option conversions and pending R&D Tax Incentives, and complements the company's ongoing 72-patient Phase 1b/2a Basket-design Study in Australia.

Entropy Neurodynamics Limited (ASX:ENP), trading at $0.040 and up 2.56% on the day, has announced it has signed a pre-Clinical Trial Agreement with the University of California, San Francisco (UCSF) to develop a Phase 2 clinical trial comparing the Company's proprietary TRP-8803, an IV-infused formulation of psilocin, against escitalopram, marketed as Lexapro, in patients with Major Depressive Disorder. The trial represents an expansion of the Company's clinical development program into the United States.

Trial Design and Rationale

The proposed head-to-head trial will recruit up to 80 young adults in the US with Major Depressive Disorder, comparing TRP-8803 against escitalopram, the most widely prescribed antidepressant in the US, with depression severity assessed over eight weeks and six months. The Company noted that escitalopram was prescribed approximately 37 million times to 8.8 million patients in the US in 2023, while around 21 million US adults experience a major depressive episode annually, with prevalence highest among 18 to 25-year-olds at 18.6%.

The trial is intended to evaluate whether a limited course of precision-controlled TRP-8803 treatment can deliver meaningful clinical and functional outcomes compared with conventional daily SSRI treatment, using established depression measures alongside treatment adherence, tolerability and safety assessments. Secondary measures will assess patient wellbeing, meaning and connectedness, and social and work functioning, with EEG measures also planned to examine potential mechanistic differences between IV psilocin and conventional SSRI treatment. Unlike much prior research into novel depression therapies, which has focused on treatment-resistant patients, this trial is designed to evaluate TRP-8803 at an earlier stage of the depression treatment pathway.

Leadership and Regulatory Pathway

The trial will be led by Professor Robin Carhart-Harris as Principal Investigator, the Ralph Metzner Distinguished Professor of Neurology and Psychiatry at UCSF, who the Company describes as having authored a landmark New England Journal of Medicine trial directly comparing psilocybin therapy with escitalopram in patients with moderate-to-severe MDD. Under the pre-CTA, Entropy and UCSF will work to develop the clinical trial protocol, informed consent materials and electronic data capture forms.

Entropy will act as the FDA Investigational New Drug sponsor and, with UCSF's support, progress regulatory activities required to support commencement of the trial in the United States. The Company said that, subject to FDA clearance, establishing an IND for TRP-8803 would provide a broader US regulatory foundation that could support further clinical development, including studies informed by data from its ongoing 72-patient, eight-indication Phase 1b/2a Basket-design Study being conducted with Swinburne University of Technology in Australia. BioCina will manufacture the GMP-grade TRP-8803 and matched placebo vials for the proposed US trial.

Next Steps and Funding

Next steps include finalising the clinical trial protocol and informed consent with UCSF, scheduling a pre-IND meeting with the FDA, submitting an IND application, and finalising a Clinical Trial Research Agreement with UCSF following FDA clearance of the trial protocol. The trial is expected to commence in the first half of calendar year 2027 and will be funded from the Company's existing cash reserves, option conversions and pending R&D Tax Incentives.

CEO and Executive Director Jason Carroll described the trial as significantly expanding the clinical and regulatory pathway being built around TRP-8803, noting the opportunity to evaluate the treatment directly against an established antidepressant in a younger patient population earlier in the course of the condition.

Conclusion

Entropy Neurodynamics' pre-Clinical Trial Agreement with UCSF sets up a proposed US Phase 2 trial directly comparing TRP-8803 with a widely used antidepressant, led by a prominent researcher in the psychedelic therapy field, and forms part of a broader strategy to establish a US regulatory pathway alongside the Company's existing Australian clinical program. The trial remains contingent on further protocol development, an FDA pre-IND meeting and IND submission, with the Company targeting a start in the first half of calendar 2027.